EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied

Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine

The money will be donated to the United Nations Children’s Fund (UNICEF)

Daiichi Sankyo commences trial for booster mRNA vaccine against Covid-19

DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio

Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy

Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab

Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan

It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan